C
25.38
0.53 (2.13%)
| Previous Close | 24.85 |
| Open | 25.08 |
| Volume | 875,340 |
| Avg. Volume (3M) | 1,579,604 |
| Market Cap | 3,751,669,760 |
| Price / Sales | 219.80 |
| Price / Book | 12.13 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Mixed | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2025 | 19,963,157 |
| Index Venture Life Associates Vi Ltd | 30 Sep 2025 | 9,961,789 |
| General Atlantic, L.P. | 30 Sep 2025 | 9,681,818 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Oppenheimer, 144.29%) | Buy |
| Median | 42.00 (65.49%) | |
| Low | 35.00 (Wells Fargo, 37.90%) | Buy |
| 35.00 (Stephens & Co., 37.90%) | Buy | |
| Average | 43.40 (71.00%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 27.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 10 Dec 2025 | 62.00 (144.29%) | Buy | 29.57 |
| B. Riley Securities | 01 Dec 2025 | 42.00 (65.48%) | Buy | 28.47 |
| Guggenheim | 18 Nov 2025 | 43.00 (69.42%) | Buy | 28.36 |
| 06 Oct 2025 | 28.00 (10.32%) | Buy | 23.00 | |
| Wells Fargo | 13 Nov 2025 | 35.00 (37.90%) | Buy | 25.97 |
| 07 Nov 2025 | 30.00 (18.20%) | Buy | 22.12 | |
| Stephens & Co. | 28 Oct 2025 | 35.00 (37.90%) | Buy | 25.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |